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Introduction
Severe sepsis, a clinical syndrome that complicates the course of  infection, is a leading cause of  mortality 
in the US (1, 2). The pathogenesis of  lethal sepsis is mediated by HMGB1 and other cytokines that damage 
cells and impair physiological homeostasis. The inflammatory responses to infection and tissue inflam-
mation are enhanced by exogenously derived pathogen-associated molecular pattern molecules (PAMPs), 
including bacterial peptidoglycan, endotoxin, and CpG-DNA, and by endogenously derived damage-as-
sociated molecular pattern molecules (DAMPs), including HMGB1 (3–9). HMGB1 is a central mediator 
of  lethal infection and injury (5, 10). The protein harbors 3 conserved cysteine residues at position 23, 45, 
and 106, and the redox state of  these cysteines determine whether HMGB1 functions as a chemokine or 
as a proinflammatory cytokine (11–14). HMGB1, actively secreted by activated immune cells or passively 
released from dying cells, is a mixture of  redox isoforms with distinct posttranslational modifications (5, 15, 
16). Administration of  anti-HMGB1 antibodies confers significant protection in animal models of  experi-
mental sepsis, endotoxemia, ischemia reperfusion injury, trauma, hepatitis, and other syndromes (3–5, 17).
Another DAMP, extracellular (free) hemoglobin, is also significantly increased in trauma, burn injury, 
blood transfusion, cardiopulmonary bypass, infection, and other clinical syndromes (18–20). Increased 
extracellular hemoglobin significantly amplifies PAMP-mediated cytokine production, organ damage, and 
mortality (7–9, 18–20). Evolution has conferred mammals with redundant counterregulatory mechanisms 
to protect against the toxicity of  extracellular hemoglobin, primarily by binding to haptoglobin, a 100-KDa 
hemoglobin binding protein produced in the liver and secreted into the circulation. Haptoglobin, comprised 
of  two α and two β chains linked by disulfide bonds, is the product of  gene polymorphisms that yield 3 
Secreted by activated cells or passively released by damaged cells, extracellular HMGB1 is a 
prototypical damage-associated molecular pattern (DAMP) inflammatory mediator. During the 
course of developing extracorporeal approaches to treating injury and infection, we inadvertently 
discovered that haptoglobin, the acute phase protein that binds extracellular hemoglobin and 
targets cellular uptake through CD163, also binds HMGB1. Haptoglobin-HMGB1 complexes elicit 
the production of antiinflammatory enzymes (heme oxygenase-1) and cytokines (e.g., IL-10) in WT 
but not in CD163-deficient macrophages. Genetic disruption of haptoglobin or CD163 expression 
significantly enhances mortality rates in standardized models of intra-abdominal sepsis in mice. 
Administration of haptoglobin to WT and to haptoglobin gene-deficient animals confers significant 
protection. These findings reveal a mechanism for haptoglobin modulation of the inflammatory 
action of HMGB1, with significant implications for developing experimental strategies targeting 
HMGB1-dependent inflammatory diseases.
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common protein phenotypes, termed Hp1-1, Hp2-2, and Hp 2-1 (21). Haptoglobin binding to hemoglobin 
is among the strongest known protein-protein interactions, with extremely high–affinity Kd on the order of  
10–15 mol/l (22). Haptoglobin-hemoglobin complexes bind CD163, a receptor expressed on macrophages 
and other cells that mediates endocytosis and internalization of  the haptoglobin-hemoglobin complexes. 
This uptake mechanism also stimulates the enhanced production of  macrophage hemeoxygenase-1 (HO-1) 
and IL-10 (23–25). Genetic deletion of  haptoglobin renders animals significantly more susceptible to lethal 
endotoxemia (26). Supplementation of  haptoglobin prevents free hemoglobin–induced hypertension and 
oxidative kidney damage, as well as blood transfusion–mediated vascular injury and kidney dysfunction 
(27, 28). Haptoglobin is approved as an adjuvant therapy for patients in Japan with trauma, burns, and 
transfusion-related hemolysis (29).
Accordingly, here we reasoned that removal of  free hemoglobin would be protective against tissue dam-
age and lethality in sepsis (18). To study this hypothesis, we developed an extracorporeal haptoglobin affin-
ity chromatography method to remove extracellular hemoglobin in rodents with sepsis from cecal ligation 
and puncture (CLP). Surprisingly, we observed that haptoglobin-affinity chromatography extracted large 
amounts of  HMGB1 from the blood of  septic rats. Studies of  underlying mechanisms indicate that hap-
toglobin forms a complex with HMGB1 to stimulate macrophage HO-1 and IL-10 production through a 
CD163-dependent mechanism that confers significant protection against the lethality of  HMGB1 in sepsis.
Results
Identification of  haptoglobin as an HMGB1 binding protein. As extracellular (free) hemoglobin is elevated and 
worsens outcome in sepsis (18), we developed an extracorporeal hemoperfusion device by conjugating hap-
toglobin to sepharose beads in order to sequester the circulating free hemoglobin in septic animals induced 
by cecal perforation. Analysis of  proteins extracted from the haptoglobin beads confirmed the presence of  
hemoglobin using an immunoblot assay. Surprisingly, however, SDS-PAGE gel analysis of  haptoglobin 
binding proteins in the eluate also revealed large quantities of  a 30-kDa protein, which was identified as 
HMGB1 by amino acid sequence analysis (data not shown) and immunoblotting (Figure 1A). To verify 
the HMGB1 binding properties of  haptoglobin, the HMGB1-haptoglobin complexes were immune pre-
cipitated using anti-haptoglobin antibodies. The coimmunoprecipitation of  HMGB1 with haptoglobin was 
confirmed by Western blotting using anti-HMGB1 antibodies (Figure 1B, lane 3). Using surface plasmon 
resonance, we further observed that the binding affinity (Kd) of  HMGB1 to haptoglobin was around 64 nM 
regardless of  whether haptoglobin or HMGB1 was immobilized on the sensor chip (Figure 1C and data 
not shown).
Haptoglobin binds the proinflammatory forms of  HMGB1. HMGB1 contains 3 cysteine residues at posi-
tion 23, 45, and 106, and HMGB1 receptor interaction is determined by the cysteine redox state. Fully 
reduced extracellular HMGB1 is chemotactic by specific interaction and signal transduction via CXCL12/
SDF1 pathways, whereas disulfide HMGB1 is proinflammatory by binding and signaling via MD2-TLR4 
to enhance macrophage cytokine production. The sulfonyl (fully oxidized) molecule has no known bio-
logical activity (15). Haptoglobin effectively binds fully reduced and disulfide HMGB1 but not the fully 
oxidized sulfonyl HMGB1 (Figure 1D). Nuclear magnetic resonance (NMR) analysis confirmed the results 
observed from immunoprecipitation, revealing that haptoglobin interacts with the HMGB1 Box A (Figure 
1E). NMR analyses also showed significant chemical shift perturbations for 10 amino acids residing in or 
near the Box A when haptoglobin binds HMGB1: (F [phenylalanine] 18, T [threonine] 22, R [arginine] 24, 
E [glutamic acid] 25, K [lysine] 28, H [histidine] 31, A [alanine] 54, K55, A126, and G [glycine] 130). The 
localization of  these amino acids within the HMGB1 Box A region (amino acids 8–78) is shown in Figure 
1F. Finally, we observed HMGB1-haptoglobin complexes in human serum from patients with severe sep-
sis by coimmunoprecipitation using haptoglobin-specific antibodies (Figure 1G). Together, these findings 
indicate that haptoglobin forms a protein complex with the proinflammatory, disulfide HMGB1 in sepsis.
Haptoglobin disruption impairs survival during lethal sepsis, and haptoglobin administration confers protection. 
To assess the functional role of  haptoglobin binding to HMGB1 in sepsis, we subjected haptoglobin KO 
mice to CLP-induced sepsis. Haptoglobin KO animals were significantly more susceptible to lethal sepsis 
as compared with WT littermates (survival = 34% in haptoglobin KO mice vs. 75% in WT mice, n = 15 per 
group) (Figure 2A). The disruption of  haptoglobin expression led to a transient elevation of  extracellular 
hemoglobin for 2–7 days, but HMGB1 levels were increased for at least 2 weeks (Figure 2B). Administra-
tion of  haptoglobin (500 μg/mouse/day, i.p.) once daily for 3 days beginning 24 hours after CLP surgery 
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significantly improved survival (63% survival in haptoglobin-treated vs. 33% in control group; P < 0.05) 
(Figure 2C, upper). Most animals treated with haptoglobin were alert and active, whereas most of  the vehi-
cle-treated control animals exhibited signs of  sickness syndrome with behavioral withdrawal, piloerection, 
and group huddling. Administration of  haptoglobin to septic haptoglobin KO animals also conferred sig-
Figure 1. Haptoglobin (Hp) binds HMGB1. (A) Rats were subjected to CLP to induce sepsis and subsequently connected to an extracorporeal pump to filter 
blood through human haptoglobin–conjugated (Hp) or empty beads for 1 hour. Proteins bound to Hp or empty beads were eluted and subjected to Western 
blot analysis using anti-HMGB1 antibodies. Data are representative from 3 repeats. (B) Human Hp and HMGB1 was mixed and applied to beads coupled 
with anti–human Hp antibody or control (empty beads). Proteins bound to the beads were analyzed by Western blot probed with anti-HMGB1 antibodies. 
Data are representative from 5 experiments. (C) Human Hp was immobilized on the sensor chip, and binding to HMGB1 was assessed. The apparent Kd is 
~64 nM. Data are presented as response units over time (Sec) and representative of 3 experiments. (D) Human Hp–coupled beads were incubated with 
various HMGB1 isoforms. Elutes were analyzed by Western blot using anti-HMGB1 mAbs. Data are representative from 6 repeats. (E) Upper: Schematics 
of human HMGB1 structure. Middle/lower: nuclear magnetic resonance (NMR) analysis of disulfide (middle) or sulfonyl (lower) Δ30-HMGB1 in complex 
with human Hp. Chemical shift perturbation of disulfide or sulfonyl Δ30-HMGB1 in complex with Hp is plotted as a function of residue number of HMGB1. 
Perturbations in chemical shift above 0.1 are considered a significant interaction (46). The majority of interacting amino acids are located within HMGB1 
Box A. Data are representative from 3 repeats. (F) Upper: 15N-1H-heteronuclear single quantum coherence (HSQC) spectra for disulfide Δ30-HMGB1 in the 
presence or absence of Hp. HMGB1 residues (10 amino acids) showing significant chemical shift perturbations due to Hp binding are labeled. Middle: Rep-
resentative 15N-HSQC spectra of disulfide Δ30-HMGB1 free (black) and in complex with haptoglobin (red); residues showing chemical shift changes upon 
complex formation are circled. Lower: 15N-HSQC spectra of sulfonyl Δ30-HMGB1 free (black) and in complex with Hp (red). Residues showing chemical shift 
changes seen with disulfide Δ30-HMGB1 upon complex formation with Hp are circled for comparison. Nonoverlapping black and red resonance spectra 
indicate a significant chemical shift and, hence, an interaction between proteins via that amino acid. (G) Serum samples (10 μl) from healthy individuals 
or sepsis patients were incubated with beads conjugated to anti–human Hp mAbs or empty (20 μl drained beads). Eluates were probed with anti-HMGB1 
(upper) and anti–human Hp (lower) antibodies using Western blot analysis. Data are representative from 5 samples each.
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nificant protection against lethality (Figure 2D, upper). Haptoglobin administration to septic animals sig-
nificantly decreased extracellular hemoglobin, HMGB1, and IL-6 levels as compared with vehicle-treated 
animals in both WT and haptoglobin KO mice (Figure 2, C and D, lower). Administration of  neutralizing 
anti-HMGB1 mAbs also conferred significant protection in haptoglobin KO mice (12% survival rate in 
Figure 2. Protective role of haptoglobin in lethal sepsis. (A) Disruption of haptoglobin expression renders mice more susceptible to lethal sepsis. Male 
WT (C57BL/6) and haptoglobin (Hp) KO mice (8–12 weeks old) were subjected to cecal ligation and puncture (CLP) surgery, and survival was monitored for 
2 weeks (n = 15 mice per group). *P < 0.05 vs. WT group (Fisher’s exact test). (B) KO of Hp prolongs CLP-induced systemic accumulation of HMGB1 but not 
free hemoglobin. Male WT (C57BL/6) and Hp KO mice were subjected to CLP and euthanized at the indicated time points; serum-free hemoglobin and 
HMGB1 levels were measured. Data are from 3 (for day 21), 6 (for days 0, 2, and 14), and 7 (for day 7) mice at each time point. *P < 0.05, ***P < 0.001 vs. 
WT group (t test). (C and D) Administration of haptoglobin confers protection against sepsis lethality and reduces inflammation in WT and Hp KO mice. 
Upper: Male BALB/c or Hp KO mice were subjected to CLP surgery, and Hp was administered at 0.5 mg/mouse (for WT mice) or 0.2 mg/mouse (for Hp KO 
mice) in 200 μl volume, injected i.p. once a day for 3 days starting at 24 hours after CLP surgery. Mice in control group received vehicle (PBS) only. Survival 
was monitored for 2 weeks (n = 22 mice per group). *P < 0.05 vs. vehicle-treated group (Fisher’s exact test). Lower: Male WT (C57BL/6) or Hp KO mice 
were subjected to CLP surgery and received Hp (0.5 mg/mouse) or vehicle (PBS) i.p. at 24 and 36 hours after CLP surgery, and mice were euthanized at 48 
hours after CLP. Sera were isolated for analyses. n = 7 (for WT group) and 8 (for Hp KO group) mice per group. *P < 0.05 vs. CLP-vehicle group (t test). (E) 
HMGB1-neutralizing antibodies confer protection against lethal sepsis in Hp KO mice. Hp KO mice (male, 8–12 weeks old) were subjected to CLP surgery, 
and neutralizing anti-HMGB1 mAbs or nonimmune mouse IgG were administered at 50 μg/mouse in 200 μl PBS, injected i.p. once a day for 3 days starting 
at 24 hours after CLP surgery. Survival was monitored for 2 weeks (n = 16 per group). *P < 0.05 vs. IgG control group (Fisher’s exact test).
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PBS-treated CLP sepsis mice vs. 56% in animals that received anti-HMGB1 antibody; P < 0.05, n = 16 
mice per group) (Figure 2E). Together, these findings indicate that haptoglobin confers protection against 
sepsis by attenuating HMGB-mediated lethality.
Haptoglobin inhibits HMGB1-induced cytokine release from macrophages via CD163. To elucidate the mech-
anism of  haptoglobin-HMGB1 complex in sepsis, we studied haptoglobin-HMGB1 complexes in murine 
macrophage-like RAW 264.7 cells and primary human macrophages. Although HMGB1 alone did not 
induce apoptosis and haptoglobin alone did not affect TNF release, haptoglobin dose-dependently inhib-
ited HMGB1-induced TNF mRNA expression and TNF and IL-8 protein secretion (Figure 3, A and B). 
The haptoglobin concentration that inhibited 50% of  TNF and IL-8 secretion (EC50) was approximately 
20 μg/ml when macrophages were stimulated by HMGB1 at 2 μg/ml (Figure 3B). Haptoglobin also sig-
nificantly reduced HMGB1-induced cytokines or chemokines such as IL-6, MIG, and MCP-2, but did not 
significantly alter others (e.g., growth-related oncogene, GRO) (data not shown). Reasoning that CD163 is 
an evolutionarily conserved scavenger receptor for haptoglobin-mediated removal of  hemoglobin, we inves-
tigated whether the genetic deletion of  CD163 would affect haptoglobin-HMGB1 in sepsis (25). Disulfide 
HMGB1 alone induced IL-10 release from WT and CD163 KO macrophages, indicating that CD163 defi-
ciency does not impair TLR4/MD2 signaling (30) (Figure 4A). However, genetic deletion of  CD163 inhib-
ited haptoglobin-HMGB1 complex–induced IL-10 secretion and almost completely abolished haptoglobin- 
and HMGB1-induced HO-1 expression (Figure 4A). Taken together, these experimental data indicate that 
CD163 is required for haptoglobin-HMGB1 complex–induced IL-10 and HO-1 production. CD163 KO 
mice were significantly more susceptible to sepsis lethality as compared with age-, sex-, and genetic back-
ground–matched WT mice (survival = 80% in WT animals vs. 33% in CD163 KO mice; P < 0.05, n = 18 
or 20 per group, Figure 4B). The CD163 KO mice died between days 4–14 after the initiation of  sepsis, a 
time frame that corresponds closely with the period of  increased HMGB1 levels in these CD163 KO mice 
(Figure 4C). Serum IL-6 levels were comparable between CD163 KO and CD163-competent mice (Figure 
4C), whereas serum levels of  IL-10, IL-1β, and TNF were not detectable in these animals. Together with 
the other results, these findings indicate that CD163 is required for the haptoglobin-dependent protection 
against HMGB1-mediated lethality in sepsis.
Haptoglobin-HMGB1 complexes bind CD163 to induce HO-1 and IL-10 expression. Surface plasmon reso-
Figure 3. Haptoglobin attenuates HMGB1-induced TNF expression and secretion in macrophages. (A) Upper: RAW 264.7 cells in 96-well culture plates 
were stimulated with HMGB1 (2 μg/ml) plus various amounts of haptoglobin as indicated for 16 hours. TNF release was measured (n = 5 experiments). 
Lower: For TNF mRNA measurement, RAW 264.7 cells were incubated with HMGB1 and various amounts of haptoglobin for 12 hours. TNF mRNA expres-
sion in the cells was measured by real-time quantitative PCR. Housekeeping gene HPRT was used as a control for equal loading and integrity of RNA (n = 8 
experiments). *P < 0.05, ***P < 0.001 vs. HMGB1 alone (t test). (B) Haptoglobin inhibits HMGB1-induced secretion of IL-8 and TNF in human macrophages. 
Primary human macrophages were incubated with HMGB1 (2 μg/ml) in the presence of haptoglobin at various concentrations as indicated for 16 hours. 
TNF and IL-8 released were measured. Data are from 8 (for TNF) or 5 (for IL-8) experiments. **P < 0.01, ***P < 0.001 vs. HMGB1 alone (t test).
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nance analysis revealed that HMGB1 and haptoglobin complexes (1:1 molar ratio) bind to CD163 in a 
concentration-dependent manner with an apparent Kd of  130 nM. In contrast, and as previously reported, 
haptoglobin alone did not bind to CD163 (25). In the absence of  haptoglobin, HMGB1 bound to CD163 
with a much lower affinity (Kd >1 μM) (Figure 5A and data not shown). To further understand the biolog-
ical consequence of  haptoglobin and HMGB1 interaction, we examined the effect of  these complexes on 
HO-1 and IL-10 expression in human monocyte THP-1 cells. Similar to the hemoglobin and haptoglobin 
complexes, the HMGB1 and haptoglobin complexes also induced a significant increase of  IL-10 secretion 
and HO-1 expression, as compared with HMGB1 stimulation alone (Figure 5B). We also studied human 
macrophages transduced with CD163-specific shRNA and observed that the levels of  CD163 expression 
were reduced by >90% at 72 hours after transduction; subsequent HMGB1- and haptoglobin-induced 
HO-1 expression and IL-10 secretion were almost completely abolished (Figure 5C). Flow cytometry 
gated analysis revealed that human primary macrophages exposed to FITC-labeled HMGB1 demonstrated 
intracellular internalization of  the labeled HMGB1 in 2% of  the macrophages, while 17% of  the cells 
contained fluorescent HMGB1 after exposure to haptoglobin and HMGB1 complexes (Figure 6A). In con-
trast, knockdown of  CD163 expression almost completely inhibited the endocytosis of  haptoglobin and 
HMGB1 complexes (Figure 6A).
Finally, we studied human embryonic kidney cells 293 (HEK 293 cells) transduced with a CD163 
plasmid to study CD163-dependent endocytosis of  HMGB1 and haptoglobin complexes. Flow cytometry 
studies demonstrated that nontransduced HEK 293 cells, without CD163, failed to endocytose FITC-
HMGB1 or FITC-HMGB1 and haptoglobin complexes. CD163-transduced cells endocytosed FITC-
HMGB1 and haptoglobin complexes (17% of  the cells) vs. FITC-HMGB1 alone (2%) (Figure 6B). In 
agreement with these findings, fluorescent-conjugated (Alexa Fluor 555–conjugated) HMGB1 was inter-
nalized by primary human macrophages when incubated for 2 hours at 37°C compared with untreated 
cells (Figure 6C). This cellular uptake of  Alexa Fluor 555–HMGB1 was further enhanced by haptoglobin 
but attenuated by pretreatment with dynasore, an endocytosis inhibitor. Together, these results indicate 
that CD163 mediates endocytic uptake of  HMGB1-haptoglobin complexes as a protective mechanism 
against HMGB1 lethality in sepsis.
Figure 4. Disruption of CD163 expression impairs haptoglobin-HMGB1 complex–induced IL-10 release and HO-1 expression and worsens CLP-induced 
sepsis. (A) KO of CD163 impairs haptoglobin-HMGB1–induced HO-1 expression and IL-10 release. Residential peritoneal macrophages from CD163 KO and 
WT (male C57BL/6) mice were stimulated with HMGB1 (1 μg/ml) alone or plus haptoglobin (3 μg/ml) for 16 hours. Extracellular levels of IL-10 and intra-
cellular HO-1 expression levels were measured by ELISAs (n = 3 experiments). *P < 0.05, ***P < 0.001 vs. WT (t test). (B) Disruption of CD163 expression 
worsens lethal sepsis. WT (C57BL/6) or CD163 KO (male, 8–12 weeks of age) were subjected to CLP surgery, and survival was monitored for 2 weeks  
(n = 18 [WT] or 20 [CD163 KO] per group). *P < 0.05 vs. WT (Fisher’s exact test). (C) Deletion of CD163 sustains sepsis-induced elevation of circulating 
HMGB1 levels. WT (C57BL/6) and CD163 KO mice (male, 8–12 weeks old) were subjected to CLP and euthanized at indicated time points; serum HMGB1 and 
IL-6 levels were measured. n = 6 (for day 3), 7 (for days 0, 7, and 14), and 8 (for days 1 and 20) mice at each time point. *P < 0.05, **P < 0.01, ***P < 0.001 
vs. WT group (t test).
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Discussion
“Haptoglobin” is derived from the Greek word haptein, meaning to fasten or bind, reflecting the excep-
tional capacity to capture free hemoglobin. Extracellular haptoglobin serves as the major plasma protein 
in capturing hemoglobin, and the haptoglobin-hemoglobin complexes are subsequently removed from the 
circulation by CD163-positive macrophages in the liver, spleen, and BM. Once ingested, hemoglobin is 
transferred to early endosomes and degraded into amino acids and heme, which is further metabolized by 
the HO-1 enzyme to produce antiinflammatory metabolites (carbon monoxide [CO], ferrous iron [Fe2+], 
and biliverdin) (31). As reported here, we discovered that haptoglobin also binds HMGB1 and confers pro-
tection against HMGB1-mediated lethality in sepsis through a CD163-dependent mechanism (Figure 7).
The synthesis of  haptoglobin and other acute phase protein in the liver during infection and injury is 
upregulated by IL-1, IL-6, and other cytokines. We found that disruption of  haptoglobin expression sig-
nificantly increased the mortality of  sepsis and prolonged the exposure time to elevated HMGB1 levels as 
compared with WT controls. Administration of  haptoglobin conferred significant protection against lethal 
sepsis in both WT and haptoglobin KO mice. Although it remains elusive whether there is a preference for 
any haptoglobin phenotype (Hp 1-1, 2-1, and 2-2) to bind HMGB1. A large body of  prior work established 
the pathogenic role of  extracellular HMGB1 in sepsis and other animal models of  infectious and sterile 
inflammatory diseases (5, 6). HMGB1 antagonists including neutralizing antibodies and peptide antag-
onists (e.g., the recombinant Box A domain), as well as small chemical inhibitors of  HMGB1 release or 
actions, confer protection and have established the damaging role of  HMGB1 in pathogenesis (3, 30). Here, 
administration of  HMGB1-neutralizing antibodies to haptoglobin KO mice conferred significant protec-
tion by targeting the persistently elevated HMGB1 levels.
CD163 is a scavenger receptor expressed on monocytes/macrophages and in relatively low abundance 
Figure 5. HMGB1 and haptoglobin complexes 
signal through CD163 to induce HO-1 and 
IL-10 expression in macrophages. (A) Surface 
plasmon resonance analysis of HMGB1 and 
haptoglobin (Hp) binding to CD163. Recombi-
nant human CD163 was coated on the sensor 
chip; the mixture of HMGB1 and Hp (1:1 molar 
ratio) at concentrations of 32, 65, 125, or 250 
nM flowed over the chip to measure the binding 
affinity to CD163 (Kd is approximately 130 nM). 
Data are representative of 3 experiments. (B) 
Hp enhances HMGB1-induced HO-1 expression 
and IL-10 release. Human monocytic THP-1 cells 
were treated with dexamethasone (2.5 × 10–7 
M) for 2 days to induce CD163 expression and 
then stimulated with HMGB1 alone (5 μg/ml) or 
plus haptoglobin (15 μg/ml) at 37°C for 16 hours. 
After incubation, extracellular levels of IL-10 
were measured by ELISA. Intracellular levels of 
HO-1 and β-actin were measured by Western 
blot. Data are expressed as folds of unstimu-
lated group after normalization to β-actin (n =3 
experiments). **P < 0.01, ***P < 0.001 vs. HMGB1 
alone (t test). (C) Knockdown of CD163 impairs Hp 
and HMGB1-induced IL-10 and HO-1 expression. 
Primary human macrophages were transduced 
with specific shRNA lentiviral particles targeting 
CD163 or vector alone (control). At 72 hours after 
transduction, cells were stimulated with HMGB1 
(1 μg/ml) with or without Hp (3 μg/ml) for 16 
hours. The expression of CD163, HO-1, and β-actin 
in cell lysate was measured by Western blot. Left: 
representative blots. Right: Data for HO-1 expres-
sion are presented as folds of unstimulated group 
after normalization to β-actin. Supernatants were 
collected to measure IL-10 release (n = 3 experi-
ments). ***P < 0.001 vs. control (t test).
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in quiescent circulating monocytes. CD163 expression is enhanced by glucocorticoids, antiinflammatory 
cytokines (e.g., IL-10), or growth factors that can promote monocyte-to-macrophage differentiation (e.g., 
macrophage CSF, M-CSF) (32, 33). The expression of  CD163 is downregulated by proinflammatory 
cyto kines (e.g., IFN-γ) and growth factors that induce monocyte to DC differentiation (e.g., granulocyte 
M-CSF, GM-CSF) (34). CD163 is abundant in mature tissue macrophages including Kupffer cells in the 
liver, red pulp macrophages in the spleen, resident BM macrophages, and alveolar macrophages in the 
lungs (34, 35). CD163 is also a receptor for cytokine TNF-like weak inducer of  apoptosis (TWEAK, a 
secreted cytokine belonging to the TNF super-family) (36, 37). CD163 can be shed as a soluble protein, but 
little is known about the biological functions of  the soluble CD163 (reviewed by ref. 37). At present, our in 
vivo studies do not exclude the possibility that free hemoglobin and HMGB1 synergize to activate proin-
flammatory responses, which could be similarly downmodulated by the common haptoglobin-CD163 axis. 
Other plasma proteins that can bind HMGB1 and confer protection include thrombomodulin (38), soluble 
receptor for advanced glycation end products (s-RAGE) (39), and Siglec-10/CD24 (40). Our investigation 
does reveal a mechanism by which haptoglobin negatively modulates the proinflammatory properties of  
HMGB1, a critically important mediator of  infection- and injury-elicited inflammatory diseases (10).
Thus, haptoglobin is an endogenous HMGB1 binding protein that directs HMGB1 to a CD163- 
dependent receptor pathway that activates antiinflammatory signaling in the monocyte-macrophage lin-
eage. Since the administration of  haptoglobin conferred significant protection against CLP-induced sepsis 
lethality in both WT and haptoglobin KO mice, it will be interesting to assess the efficacy of  haptoglo-
bin-based therapies in other HMGB1-dependent inflammatory diseases.
Methods
Reagents. Human haptoglobin (from pooled human plasma, a mixture of  1-1, 2-1, and 2-2 phenotype, cat-
Figure 6. Modulation of CD163 expression divergently affects haptoglobin-mediated HMGB1 endocytosis. (A) Knockdown of CD163 impairs endocytosis 
of haptoglobin and HMGB1 complexes. The endocytosis of HMGB1 and haptoglobin complexes was measured by flow cytometric analysis. Primary human 
macrophages were transduced with CD163 shRNA lentiviral or vector alone (control) and incubated with FITC-labeled HMGB1 (1 μg/ml) plus haptoglobin (3 
μg/ml) for 30 minutes. Endocytosis of FITC-HMGB1 was evaluated by measuring the fluorescence intensity of FITC-labeled protein as a function of CD163-
PE signals. Data are representative of 5 experiments. (B) Overexpression of CD163 enhances endocytosis of haptoglobin and HMGB1 complexes. HEK 293 
cells were transduced with human CD163 plasmid and incubated with FITC-HMGB1 alone (1 μg/ml) or a mixture of FITC-HMGB1 (1 μg/ml) and haptoglobin 
(3 μg/ml) for 30 minutes at 37°C. Endocytosis of FITC-HMGB1 was evaluated as described above, and data are representative of 4 repeats. (C) Dynasore 
(DYN) inhibits endocytosis of HMGB1 and haptoglobin complexes. Human macrophages on cover slips were incubated with Alexa Fluor 555–labeled HMGB1 
alone (1 μg/ml) or in complex with haptoglobin (3 μg/ml) for 2 hours at 37°C. Dynasore (8 μM) was preincubated with cells for 30 minutes before the addi-
tion of HMGB1 and/or haptoglobin. Upper: Endocytic uptake of HMGB1 was visualized via Carl Zeiss fluorescence microscope (red). Nuclei were counter-
stained with DAPI (blue). Lower: Corresponding phase contrast image of cells. Scale bars: 10 µm. Data are representative from 8 independent experiments.
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alog 3536), REDExtract-N-Amp Tissue PCR kit (catalog XNATS), Triton X-114, imidazole, monoclonal 
anti-human haptoglobin antibodies (catalog H6395), nonimmune mouse IgG, Drabkin’s reagents (catalog 
D5941), human M-CSF, DAPI, and dexamethasone (catalog D2915) were purchased from Sigma-Aldrich. 
TACS MTT Cell proliferation assay kit was from Trevigen. Trizol reagent was from Invitrogen. The Rever-
tAid First Strand cDNA Synthesis Kit was from Fermentas. SYBR Premix Ex Taq II was from Takara Bio 
Inc. Thioglycollate medium was purchased from BD Biosciences. Primers for quantitative PCR (qPCR), 
trypsin-EDTA, and carbenicillin were from Invitrogen. Protein A/G agarose and isopropyl-D-thiogalacto-
pyranoside (IPTG) were purchased from Pierce. NHS-activated Sepharose 4 fast flow beads were obtained 
from GE Healthcare (catalog 17-0906-01). E. coli strain DH5α was from Novagen. Recombinant human 
CD163 protein, CD163 expression plasmid (SC117495, NM_004244.3), and MegaTran 1.0 transfection 
reagent were purchased from Origene. Antibodies for human HO-1 (catalog ab52946) and CD163 (cata-
log MCA1853) were from Abcam and Serotec, respectively. Anti–human CD163-PE antibody was from 
BioLegend. FITC antibody labeling kit was from Thermo Scientific. Dynasore was from Tocris Bioscience.
Preparations of  recombinant HMGB1, redox-modified HMGB1, and HMGB1 mAbs. Recombinant HMGB1 
was expressed in E. coli and purified to homogeneity as previously described (41, 42). HMGB1-FITC was 
prepared by using a Pierce FITC Antibody Labeling Kit (Thermo Scientific). Anti-HMGB1 mAbs were gen-
erated as described previously (17). Nonimmune mouse IgG was used as isotype control in experiments when 
anti-HMGB1 mAb was used. HMGB1 with redox modifications was created as described previously (14).
Cell culture. Murine macrophage–like RAW 264.7, human acute monocytic leukemia cell line THP-1, 
and HEK 293 cells were obtained from ATCC. Cells were used at 90% confluence, and treatment was 
carried out in serum-free Opti-MEM I medium (Invitrogen). Human primary monocytes were purified 
by density gradient centrifugation through Ficoll from blood donated by normal individuals to the Long 
Island Blood Bank (New York Blood Center, Melville, New York, USA). Cells were allowed to differentiate 
into macrophages for 7 days in complete DMEM medium and 1 ng/ml M-CSF as described previously 
(43). Primary mouse residential macrophages were obtained by washing the peritoneal cavity with 5 ml 
sterile PBS. Thioglycollate-elicited mouse macrophages were obtained as previously described (43). Cells 
were plated in culture dishes and used after seeding overnight. Experiments were carried out in Opti-MEM 
I medium. Cell apoptosis was measured using TACS MTT cell proliferation assay.
Measurements of  CD163 and HO-1 expression, levels of  cytokines, serum hemoglobin, and haptoglobin. THP-1 
cells were incubated with dexamethasone for 2 days to induce CD163 expression. Cells were exposed to 
HMGB1 in the presence or absence of  haptoglobin for 16 hours, and the expression of  HO-1 and CD163 
in cell lysate was measured by Western blot analysis as previously described (24). In some experiments, 
Figure 7. Haptoglobin as a negative regulator of HMGB1. During 
infection or injury, HMGB1 is actively secreted or passively released 
outside of the cells. In the presence of haptoglobin, HMGB1 is 
captured; the haptoglobin and HMGB1 complexes act via CD163 to 
elicit an anti-inflammatory response and parallel endocytosis of 
HMGB1-haptoglobin complexes. Thus, haptoglobin, a liver-derived 
acute phase protein, acts as an endogenous HMGB1 inhibitor via a 
CD163-dependent antiinflammatory pathway.
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HO-1 expression in cell lysate was measured using ELISA kits (Enzo Life Science). HMGB1, TNF, IL-10, 
and IL-8 released in the cell culture supernatants were measured by commercially obtained ELISA kits per 
manufacturer’s instructions (IBL International and R&D Systems Inc.). In some experiments, HMGB1 
levels were measured by Western immunoblotting analysis as previously described (3, 41). The levels of  
HMGB1 were calculated with reference to standard curves generated with purified HMGB1. Cytokine 
expression profile from primary human macrophages was determined by human cytokine array C1 (Ray-
biotech) according to the manufacturer’s instructions. Twenty-two cytokines or chemokines were deter-
mined simultaneously. Serum hemoglobin levels were determined using Drabkin’s reagents (44) following 
the manufacturer’s instructions (Sigma-Aldrich). The amounts of  hemoglobin in the samples were calcu-
lated with reference to standard curves generated with purified mouse hemoglobin. Haptoglobin levels 
were measured by quantitative ELISA kits following the manufacturer’s instructions (Genway Biotech 
Inc.) or by Western blot.
Immunoprecipitation assay. Recombinant disulfide HMGB1 (10 μg) was precleared with protein A/G 
agarose (20 μl beads, 20 minutes at 4°C) and incubated with human haptoglobin (5 μg) at 4°C for 4 hours 
with gentle shaking. The mixture was added to beads (30 μl drained beads) containing either A/G agarose 
alone (control) or the same agarose coupled with anti-haptoglobin mAb overnight at 4°C. After washing 
extensively with PBS containing 0.1% Triton X-100, beads were boiled for 5 minutes and proteins bound to 
the beads were analyzed by Western blot probed with anti-HMGB1 mAbs.
To test binding of  haptoglobin to isoforms of  HMGB1, human haptoglobin was cross-linked to NHS- 
activated Sepharose 4 Fast Flow beads according to the manufacturer’s instructions (GE Healthcare). 
Approximately 16 mg haptoglobin is bound to 1 ml of  drained beads. Control (empty) beads were prepared 
the same way without adding the haptoglobin. Various HMGB1 isoforms (2 μg) were added to haptoglobin-
containing beads (10 μl per reaction) or empty beads for 2 hours at room temperature with gentle rotation. 
Samples were centrifuged, and beads were washed extensively with PBS containing 0.1% Triton X-100. 
After washing, elutes from the beads were analyzed by Western blot probed with anti-HMGB1 mAbs.
To measure HMGB1 and haptoglobin in septic human serum using immunoprecipitation assay, serum 
samples were obtained from patients with clinical signs and symptoms of  sepsis after admission to the 
Department of  Emergency Medicine, Northwell Health. As controls, blood samples were collected from 
healthy volunteers. The study was conducted in accordance with the declaration of  Helsinki and was 
approved by the IRB at the Feinstein Institute for Medical Research. Samples (10 μl, precleared with pro-
tein A/G agarose) were incubated with A/G agarose alone (control) or the same agarose coupled with 
anti–human haptoglobin mAbs overnight at 4°C. After washing extensively with PBS with 0.1% Triton 
X-100, beads were boiled for 5 minutes and proteins bound to the beads were analyzed by Western blot 
probed with monoclonal anti-HMGB1 or anti–human haptoglobin antibodies.
Endocytosis of  HMGB1 and haptoglobin complexes by CD163-expressing HEK 293 cells or primary human mac-
rophages. Transduction of  CD163 plasmid to HEK 293 cells was performed according to the manufactur-
er’s instructions. Briefly, HEK 293 cells in a 6-well plate were transduced with CD163 plasmid DNA (in 
MegaTran 1.0 reagent) for 3 hours at 37°C. The transduction reaction was terminated by washing the cells 
3 times with PBS. At 72 hours after transduction, cells were incubated with FITC-HMGB1 alone (1 μg/
ml) or plus haptoglobin (3 μg/ml) for 30 minutes at room temperature. After washing to remove any non-
specific binding of  FITC-HMGB1, cells were stained with anti–CD163-PE antibody at 4°C for 45 minutes. 
Cells were washed with PBS and then analyzed by a BD LSRFortessa cytometer (BD Biosciences).
Fluorescence microscopy. Alexa Fluor 555–labeled HMGB1 was performed according to the manufac-
turer’s instructions (Molecular Probes). To identify the haptoglobin-induced HMGB1 endocytosis process, 
primary human macrophages on coverslips were preincubated with endocytosis inhibitor Dynasore (8 μM) 
for 30 minutes (45) and then incubated with Alexa Fluor 555–labeled HMGB1 (1 μg/ml) in the presence 
and absence of  haptoglobin (3 μg/ml) for 2 hours at 37°C in a 5% CO2 incubator. The cells were rinsed with 
PBS and fixed using 4% PFA (paraformaldehyde) for 30 minutes at room temperature, stained with DAPI 
for nuclear staining, and mounted on the slide using permanent mounting medium (Vecta mount). Images 
were taken using a Carl Zeiss fluorescence microscope with a ×40 objective.
Human primary macrophages were incubated with FITC-HMGB1 (1 μg/ml) alone or plus haptoglo-
bin (3 μg/ml) for 30 minutes at 37°C. After washing with PBS to remove nonspecific binding, macrophages 
were stained with anti–CD163-PE antibody at 4°C for 45 minutes and then analyzed by a FACS Calibur 
flow cytometer. The optimal ratio of  HMGB1 to haptoglobin was determined by measuring the endocyto-
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sis of  FITC-HMGB1 (1 μg/ml) plus increasing amounts of  haptoglobin (0–10 μg/ml), and we observed the 
optimal binding is 1:1 molar ratio for HMGB1 to haptoglobin.
Surface plasmon resonance analysis. Surface plasmon resonance analysis of  binding of  HMGB1 to hap-
toglobin was conducted using the BIAcore 3000 or T200 instrument as previously described (14, 30). For 
HMGB1-haptoglobin binding analyses, purified human haptoglobin (1 μM, in 10 mM sodium acetate, 
pH 4.5) was immobilized onto the sensor chip. To evaluate binding, a series of  concentrations of  analytes 
(HMGB1 0–500 nM) were then passed over the sensor chip. The association of  analyte and ligand was 
recorded respectively by surface plasmon resonance. Results were analyzed using the software BIAeval 3.2 
(BIAcore Inc.). For the binding studies of  CD163 to the complexes of  haptoglobin and HMGB1, human 
CD163 protein was coated on the sensor chip. Increasing concentrations of  the complexes of  HMGB1 
and haptoglobin formed at 1:1 molar ratio were flowed over the sensor chip; analyses were performed in a 
similar manner as described above.
NMR analyses to determine the interacting amino acid residues between redox isoforms of  HMGB1 and haptoglo-
bin. Recombinant Δ30-HMGB1 (HMGB1 expressed minus 30 C-terminal amino acids) of  various redox 
states was produced in complex with haptoglobin, and the nature of  the interaction was examined by 
NMR. Standard heteronuclear single quantum correlation–based (HSQC-based) 3D triple resonance (1H, 
15N, and 13C) was used to assign the backbone residues as described previously (13, 46). 3D HNCO (pro-
vides the connectivity between the amide of  a residue with the carbonyl carbon of  the preceding residues) 
and HNCACO (correlates the amide resonance of  a residue with the carbonyl carbon of  the same residue, 
as well as that of  the preceding residues) experiments were used to sequentially assign the backbone NH via 
the carboxyl group. CBCACONH and HNCACB experiments were used to assign the backbone NH via 
the backbone Cα and side-chain Cβ groups. 15N- and/or 13C-labeled recombinant proteins were expressed 
in minimal media and purified by ion-exchange and size-exclusion chromatography. NMR samples were 
prepared at 10–100 μM concentrations in PBS with a final concentration of  10% D2O (deuterium oxide, 
2H2O). Samples were placed in standard 5-mm NMR tubes. Chemical shift perturbation studies were car-
ried out using either a Bruker Avance III 600 or 800 MHz NMR system equipped with triple (TCI) reso-
nance cryoprobes at 25oC (298K). All data were processed using Topspin 3.1 (Bruker) and analyzed using 
CCPN (collaborative computing project for NMR) analysis. The redox status of  cysteines on HMGB1 was 
confirmed by liquid chromatography tandem mass spectrometry as previously described (14).
CD163 shRNA lentiviral transduction of  human macrophages. Ficoll gradient–separated human mono-
cytes were differentiated for 7 days in complete DMEM medium containing 10% heat-inactivated human 
serum, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 ng/ml M-CSF in 24-well 
Primaria tissue culture plates at 5 × 105 cells/well. After screening of  5 human CD163 (NM_004244) Mis-
sion shRNA lentiviral clones using FACS analysis, the clone that showed the best knockdown efficiency 
(TRCN0000421748) was selected. The selected clone was transduced into human macrophages by spinoc-
ulation according to the manufacturer’s instructions (Sigma-Aldrich).
Animal experiments. Male Sprague-Dawley rats (8–12 weeks old) and male BALB/c, or C57BL/6 mice 
(8–12 weeks old) were obtained from Taconic Laboratories and allowed to acclimate for 7 days before use 
in the experiment.
KO (haptoglobin or CD163) and WT mice. Haptoglobin KO C57BL/6 mice were generated and provided 
by Dominique P.V. de Kleijn (Utrecht, the Netherlands). CD163 KO C57BL/6 mice were purchased from 
KOMP repository (University of  California-Davis, Davis, California, USA). Since the KO mice are all 
derived from C57BL/6 mice, small colonies of  WT C57BL/6 were maintained under the same conditions 
as the KO mice. In some experiments, BALB/c mice were used. To ascertain that newly bred animals 
had the expected gene deficiencies, we carried out genotyping on genomic DNA obtained from tail snips 
(26). Animals were anesthetized using EMLA cream (Lidocaine and prilocaine mixture, AstraZeneca LP) 
applied to the intact skin, and 1- to 2-mm tail snips were obtained. Genomic DNA was extracted using a 
tissue PCR kit. The PCR primers used for haptoglobin KO were: Neo (544 bp) forward: 5′-AGGCTATTC-
GGCTATGACTGG-3′ and reverse: 5′-CCACCATGATATTCGGCAAGC-3′. Haptoglobin (319 bp) for-
ward: 5′-CTGTGGAGTTGGGCAATGATG-3′ and reverse: 5′-AACCAAGTGCTCCACATAGCC-3′. 
The PCR amplification conditions include 95°C for 4 minutes, followed by 35 cycles of  94°C for 1 minute, 
60°C for 1 minute, 72°C for 40 seconds, and finally 10 minutes at 72°C (Applied Biosystems). The PCR 
primers for CD163 KO mice were: Neo (632 bp) forward: 5′-GCAGCCTCTGTTCCACATACACTTCA-3′ 
and reverse: 5′-ATTCTAGGCTTGCCTGCTCTCTATCG-3′. CD163 (385 bp) forward: 5′-TCACTCCT-
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GGGCTGCACGTAAAC-3′ and reverse: 5′-GATGTTATTTGCCATACAGGAGAATTG-3′. The PCR 
amplification conditions were: 94°C for 3 minutes, followed by 35 cycles of  94°C for 30 seconds, 58°C for 
30 seconds, 72°C for 40 seconds, and final extension at 72°C for 5 minutes.
CLP. WT (male, C57BL/6 or BALB/c), haptoglobin, or CD163 KO mice (male, 8–12 weeks of  age) 
were subjected to CLP procedure (3). In some experiments, survival was monitored for 2 weeks. In separate 
experiments, mice were euthanized at 1–21 days after CLP surgery through overexposure to CO2. Sera 
were isolated and stored at –20ºC until analysis. In some experiments, male WT (C57BL/6) or haptoglobin 
KO mice were subjected to CLP surgery and received haptoglobin treatment (500 μg/mouse i.p. at 24 and 
36 hours after CLP surgery), and mice were euthanized at 48 hours after CLP. Sera were isolated for analy-
ses. For other treatment studies, administration of  haptoglobin or monoclonal anti-HMGB1 antibody was 
given i.p., and survival was monitored for 2 weeks.
Perfusion studies using haptoglobin in an extracorporeal device in septic rats. CLP was performed in rats as pre-
viously described (3). At 48 hours after CLP, the septic rats were anesthetized with isofluran; both femoral 
veins were cannulated using a 24-gauge angiocatheter and connected to a sterilized miniaturized circuit 
that had been primed with heparinized saline (10 units/ml). The blood was pumped through the filter 
linked with haptoglobin or empty beads (1.5 ml beads) for 1 hour at a flow rate of  1 ml/min. The filter 
beads were then washed extensively with PBS (5 times); 2× Laemmli buffer was added to the beads to elute 
bound proteins. Western blot was performed on bead eluate using anti-HMGB1 antibodies. The blood was 
pumped through the filter linked with haptoglobin or empty beads (1.5 ml beads) for 1 hour at a flow rate 
of  1 ml/min. The filter beads were then washed extensively with saline. After washing with PBS 5 times, 
2× Laemmli buffer was added to the beads to elute bound proteins. Western blot was performed on bead 
eluate using anti-HMGB1 antibodies.
Statistics. Data are presented as means ± SEM unless otherwise stated. Differences between treatment 
groups were determined by Student’s t test. Differences between treatment groups in animal survival stud-
ies were determined using 2-tailed Fisher’s exact test. P values less than 0.05 were considered statistically 
significant.
Study Approval. All animal procedures were approved by the Institutional Animal Care and Use Com-
mittee. Mice were housed in the animal facility of  the Feinstein Institute for Medical Research under stan-
dard temperature and light and dark cycles.
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